"Tiotropium has a small benefit for those with moderate-severe asthma"
The December Albert Tools for Practice1 asked the question: Is tiotropium useful as an add-on therapy in asthmatic patients who are poorly controlled on an Inhaled Corticosteroid (CS) or ICS + Long-Acting Beta Agonist (LABA)?
They found that in moderate-severe asthma, uncontrolled on ICS or ICS+LABA, the addition of tiotropium prevents exacerbations for one in 18-36 patients over 4-52 weeks. Much of the research is at high risk of bias and changes in other surrogate outcomes (like FEV1) are of uncertain clinical importance.
Gems are chosen by the Goodfellow director Dr. Bruce Arroll to be either practice changing or practice maintaining. The information is educational and not clinical advice.